Publication at Second Faculty of Medicine |
2012
Abstract
The prevention of thromboembolic disease following joint replacement is standard in the Czech Republic. Orally administered antithrombotic agents are preferred to LMWH.
These drugs are also suggested by the Czech Orthopaedic Society recommendation. The newest oral antithrombotic agent is currently Apixaban, a direct Xa inhibitor.
In this article, the results of clinical studies, conducted in order to examine the dosing, efficacy and safety, are discussed. The real advantage of the medicine is its simple dosing and the possibility of late application after surgery (up to 24 hours).
The comparison with Enoxaparine – the “golden standard” seems to be more than favourable for Apixaban.